Challenges and Opportunities for Quantitative Clinical Pharmacology in Cancer Immunotherapy: Something Old, Something New, Something Borrowed, and Something Blue

Cancer immunotherapy (CIT) initiates or enhances the host immune response against cancer. Following decades of development, patients with previously few therapeutic options may now benefit from CIT. Although the quantitative clinical pharmacology (qCP) of previous classes of anticancer drugs has mat...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:CPT Pharmacometrics Syst Pharmacol
Prif Awduron: Stroh, M, Carlile, DJ, Li, C-C, Wagg, J, Ribba, B, Ramanujan, S, Jin, J, Xu, J, Charoin, J-E, Xhu, Z-X, Morcos, PN, Davis, JD, Phipps, A
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley & Sons, Ltd 2015
Pynciau:
Perspective
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4592528/
https://ncbi.nlm.nih.gov/pubmed/26451328
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/psp4.12014
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg